Inhibition of TAK1/TAB2 complex formation by costunolide attenuates obesity cardiomyopathy via the NF-κB signaling pathway

Ye, Bozhi; Chen, Xudong; Chen, Yanghao; Lin, Wante; Xu, Diyun; Fang, Zimin; Chattipakorn, Nipon; Huang, Weijian; Wang, Xu; Wu, Gaojun; Liang, Guang

doi:10.1016/j.phymed.2022.154523

Cited by 13 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anti‐inflammatory activity of Cos has been extensively reported and attributed to the inhibition of the NF‐κB and MAPK signalling pathways 22,42 . Cos was also shown to exhibit cardioprotective effect in HFD‐induced obesity mice model 43 and doxorubicin‐induced toxicity in rats via inhibiting NF‐κB inflammatory signalling pathway 23 . However, the antioxidant activity of Cos has not been precisely elucidated.…”

Section: Discussionmentioning

confidence: 99%

Costunolide alleviates hyperglycaemia‐induced diabetic cardiomyopathy via inhibiting inflammatory responses and oxidative stress

Jin

Chen

Wang

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a common metabolic disorder worldwide and has gradually become an epidemic in recent years. Elevated blood glucose levels typically cause a series of tissue injury-related events during diabetes, resulting in diabetic complications such as diabetic cardiomyopathy (DCM), diabetic nephropathy, diabetic foot disease and retinopathy. Among these diabetic complications, DCM is considered a risk factor of heart failure, known to be associated with disability and mortality in patients with diabetes. 1 DCM persistently presents as diastolic dysfunction during the early stage, progressing to systolic dysfunction in the advanced phase.

show abstract

Section: Discussionmentioning

confidence: 99%

Costunolide alleviates hyperglycaemia‐induced diabetic cardiomyopathy via inhibiting inflammatory responses and oxidative stress

Jin

Chen

Wang

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…The expression of CCL18 [109], SLAMF7 [110], GPR174 [111], CCR4 [112], POU4F2 [113]. CCR2 [114], IL2RB [115], CCL4 [116], CCL24 [117], FASLG (Fas ligand) [118], CD24 [119], TDGF1 [120], CD28 [121], IL7R [122], CYP11B1 [123], CCL5 [124], CCL3 [125], LTF (lactotransferrin) [126], GPNMB (glycoprotein nmb) [127], CD209 [128], IL2RG [129], CHIT1 [130], TAB2 [131], CD163 [132], ALOX15B [133], NMRK2 [134], HGF (hepatocyte growth factor) [135], TRPM8 [136], DIO3 [137], SIGLEC1 [138], TTR (transthyretin) [139], IL24 [140], F13A1 [141], IL9 [142], VEGFA (vascular endothelial growth factor A) [143], RASAL1 [144], ADM (adrenomedullin) [145], ANGPTL4 [146], CHI3L1 [147], LDB3 [148], CNP (2’,3’-cyclic nucleotide 3’ phosphodiesterase) [149], HES6 [150], CMTM5 [151], PLXNB3 [152], KLK8 [153], CDKN1C [154], INSIG1 [155], GREM1 [156], ATF3 [157], HK2 [158], MCAM (melanoma cell adhesion molecule) [159], SEMA4D [160], GLUL (glutamate-ammonia ligase) [161], S1PR5 [162], FN3K [163], MEIS1 [164], ADAMTS4 [165], BIN1 [166], BMP2 [167], LMNA (lamin A/C) [168], ERBB3 [169], DLL1 [170], THBS2 [171], GADD45B [172], MYH6 [173]. PNPLA3 [174], ACTN2 [175], MMP15 [176], SVEP1 [177], CPB2 [178], DYSF (dysferlin) [179], ADAMTSL2 [180], NINJ2 [181], LRP2 [106], PHLDA3 […”

Section: Discussionmentioning

confidence: 99%

“…CCR2 [461], FASLG (Fas ligand) [462], CD28 [463], LYZ (lysozyme) [464], CCL5 [465], CCL3 [466], C6 [467], MSR1 [468], HGF (hepatocyte growth factor) [469], VEGFA (vascular endothelial growth factor A) [470], ADM (adrenomedullin) [471], CR2 [472], MAG (myelin associated glycoprotein) [473], CDH1 [474], OLIG2 [475], SEMA4D [476], ADAMTS4 [477], BMP2 [478], ERBB3 [479] and NKX2-2 [480] have been identified as a hub gene in spinal cord injury in several studies. CCR2 [481], FASLG (Fas ligand) [286], CD24 [482], CD28 [483], LYZ (lysozyme) [484], IL7R [485], CCL5 [486], LTF (lactotransferrin) [487], GPNMB (glycoprotein nmb) [488], CTLA4 [489], IRF4 [490], CHIT1 [491], NPY2R [492], TAB2 [131], CD52 [302], CD163 [493], MSR1 [306], HGF (hepatocyte growth factor) [494], TRPM8 [495], TTR (transthyretin) [496], F13A1 [497], ADM (adrenomedullin) [498], COL9A3 [499], ANGPTL4 [500], CHI3L1 [501], BMP8A [502], SREBF1 [503], CDKN1C [504], INSIG1 [505], ATF3 [506], HK2 [507], TF (transferrin) [508], MOG (myelin oligodendrocyte glycoprotein) [509], ADAMTS4 [510], BMP2 [511], HSPA2 [512], LMNA (lamin A/C) [330], HSD11B1 [513], NKX2-2 [514], NHLH2 [433], FGF11 [515], ASPA (aspartoacylase) [336], FASN (fatty acid synthase) [516], PNPLA3 [517], MMP15 [518], CBR1 [519], LRP2 [520], WNT7A [340], GPR142 [521], GPD1 [343], LIPE (lipase E, hormone sensitive type) [522], CNDP1 […”

Section: Discussionmentioning

confidence: 99%

“…SLAMF1 [287], CFTR (CF transmembrane conductance regulator) [317], LMNA (lamin A/C) [330], ERBB3 [331], HGF (hepatocyte growth factor) [307] and CCL5 [293] might play an important role in the pathophysiology of diabetes mellitus. TAB2 [131], LMNA (lamin A/C) [168], ERBB3 [169], HGF (hepatocyte growth factor) [135] and CCL5 [124] were abnormally expressed in cardiovascular diseases. TAB2 [131], LMNA (lamin A/C) [330], HGF (hepatocyte growth factor) [494] and CCL5 [486] migt play an important role in the occurrence and development of obesity.…”

Section: Discussionmentioning

confidence: 99%

“…TAB2 [131], LMNA (lamin A/C) [168], ERBB3 [169], HGF (hepatocyte growth factor) [135] and CCL5 [124] were abnormally expressed in cardiovascular diseases. TAB2 [131], LMNA (lamin A/C) [330], HGF (hepatocyte growth factor) [494] and CCL5 [486] migt play an important role in the occurrence and development of obesity. CFTR (CF transmembrane conductance regulator) [380], RHOB (ras homolog family member B) [396], LMNA (lamin A/C) [388], HGF (hepatocyte growth factor) [371], CCL5 [360] and NGFR (nerve growth factor receptor) [383] were altered expression in the Alzheimer’s Disease.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Identification of candidate biomarkers and pathways associated with multiple sclerosis using bioinformatics and next generation sequencing data analysis

Vastrad,

Vastrad

2023

Preprint

View full text Add to dashboard Cite

Multiple sclerosis (MS) is the main reason for disability caused by autoimmunity. However, effective biomarkers for MS have not been identified. This study explored the molecular mechanisms and potential therapeutic targets for MS occurrence and progression using bioinformatics and next generation sequencing (NGS) data analysis. NGS data GSE138614, including patients with MS and 25 normal control samples, were obtained from Gene Expression Omnibus (GEO) database Differentially expressed genes (DEGs) were filtered and subjected to gene ontology (GO) and pathway enrichment analyses. Protein–protein interaction (PPI) network and module analyses were performed based on the DEGs. MiRNA-hub gene regulatory network and TF-hub gene regulatory network analysis were built by Cytoscape to predict the underlying microRNAs (miRNAs) and transcription factors (TFs) associated with hub genes. We also validated the identified hub genes via receiver operating characteristic (ROC) curve analysis. A total of 959 DEGs (479 up regulated genes and 480 down regulated genes) were detected. The GO terms and pathways of DEGs involve immune system process, developmental process, immune system and regulation of cholesterol biosynthesis by SREBP (SREBF). The network analysis revealed that hub genes include LCK, PYHIN1, SLAMF1, DOK2, TAB2, CFTR, RHOB, LMNA, EGLN3 and ERBB3 might be involved in the development of MS. The present investigation illustrates a characteristic gene profile in MS, which might contribute to the interpretation of the progression of MS and provide novel biomarkers and therapeutic targets for MS.

show abstract

Inhibition of STX17–SNAP29–VAMP8 complex formation by costunolide sensitizes ovarian cancer cells to cisplatin via the AMPK/mTOR signaling pathway

Liang

Tian

et al. 2023

Biochemical Pharmacology

View full text Add to dashboard Cite

Inhibition of TAK1/TAB2 complex formation by costunolide attenuates obesity cardiomyopathy via the NF-κB signaling pathway

Cited by 13 publications

References 38 publications

Costunolide alleviates hyperglycaemia‐induced diabetic cardiomyopathy via inhibiting inflammatory responses and oxidative stress

Costunolide alleviates hyperglycaemia‐induced diabetic cardiomyopathy via inhibiting inflammatory responses and oxidative stress

Identification of candidate biomarkers and pathways associated with multiple sclerosis using bioinformatics and next generation sequencing data analysis

Inhibition of STX17–SNAP29–VAMP8 complex formation by costunolide sensitizes ovarian cancer cells to cisplatin via the AMPK/mTOR signaling pathway

Contact Info

Product

Resources

About